Sten Randahl Sörensen

SARomics Biostructures AB provides protein three-dimensional structure determination and structure-based drug discovery services. The firm develops premium structural biology services. It offers crystallography services, which include crystallization screen and structure determination, nuclear magnetic resonance spectroscopy services, such as ligand binding assays/fragment screening, structure determination, and verification of the structural integrity of target protein, gene-to-structure services, such as protein cloning, expression, purification, and structure determination, kinase structures and kinobits, which include pre-made complexes of kinases with small-molecule fragments to serve as a starting point in a discovery project, structure-based drug discovery services, such as hit identification, hit optimization, and lead generation, gene-to lead services, including a combination of gene-to-structure and structure-based drug discovery, and structure-activity protein optimization services. The company was founded by Björn Ulrik Walse, Sven Anders Mikael Akke, Derek W. Logan, Salam Al-Karadaghi, and Bo Svensson in 2006 and is headquartered in Lund, Sweden.

SARomics Biostructures AB provides protein three-dimensional structure determination and structure-based drug discovery services. The firm develops premium structural biology services. It offers crystallography services, which include crystallization screen and structure determination, nuclear magnetic resonance spectroscopy services, such as ligand binding assays/fragment screening, structure determination, and verification of the structural integrity of target protein, gene-to-structure services, such as protein cloning, expression, purification, and structure determination, kinase structures and kinobits, which include pre-made complexes of kinases with small-molecule fragments to serve as a starting point in a discovery project, structure-based drug discovery services, such as hit identification, hit optimization, and lead generation, gene-to lead services, including a combination of gene-to-structure and structure-based drug discovery, and structure-activity protein optimization services. The company was founded by Björn Ulrik Walse, Sven Anders Mikael Akke, Derek W. Logan, Salam Al-Karadaghi, and Bo Svensson in 2006 and is headquartered in Lund, Sweden.

SARomics Biostructures AB provides protein three-dimensional structure determination and structure-based drug discovery services. The firm develops premium structural biology services. It offers crystallography services, which include crystallization screen and structure determination, nuclear magnetic resonance spectroscopy services, such as ligand binding assays/fragment screening, structure determination, and verification of the structural integrity of target protein, gene-to-structure services, such as protein cloning, expression, purification, and structure determination, kinase structures and kinobits, which include pre-made complexes of kinases with small-molecule fragments to serve as a starting point in a discovery project, structure-based drug discovery services, such as hit identification, hit optimization, and lead generation, gene-to lead services, including a combination of gene-to-structure and structure-based drug discovery, and structure-activity protein optimization services. The company was founded by Björn Ulrik Walse, Sven Anders Mikael Akke, Derek W. Logan, Salam Al-Karadaghi, and Bo Svensson in 2006 and is headquartered in Lund, Sweden.

SARomics Biostructures AB provides protein three-dimensional structure determination and structure-based drug discovery services. The firm develops premium structural biology services. It offers crystallography services, which include crystallization screen and structure determination, nuclear magnetic resonance spectroscopy services, such as ligand binding assays/fragment screening, structure determination, and verification of the structural integrity of target protein, gene-to-structure services, such as protein cloning, expression, purification, and structure determination, kinase structures and kinobits, which include pre-made complexes of kinases with small-molecule fragments to serve as a starting point in a discovery project, structure-based drug discovery services, such as hit identification, hit optimization, and lead generation, gene-to lead services, including a combination of gene-to-structure and structure-based drug discovery, and structure-activity protein optimization services. The company was founded by Björn Ulrik Walse, Sven Anders Mikael Akke, Derek W. Logan, Salam Al-Karadaghi, and Bo Svensson in 2006 and is headquartered in Lund, Sweden.